ClinicalTrials.gg
TerminatedNCT05501002Updated Nov 22, 2024

Pilot Study to Evaluate the CereVasc® EShunt® System in the Treatment of Communicating Hydrocephalus

An interventional study of eShunt® Implant in Hydrocephalus and Hydrocephalus, Communicating, sponsored by CereVasc Inc. Terminated at 2 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-11-22.

Sponsored by CereVasc Inc · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Low enrollment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Hydrocephalus with a site in United States — 22 open to participants now, 26 under way, none of them phase 3. Hydrocephalus · United States.

Enrollment
38th of 42
4 · median 33
Started
2022
with 2 others
No phase
31 of 77
12 open now
Registered
56th of 77
by date
Lead sponsor
2 of 77
CereVasc Inc

Among the 77 studies in Hydrocephalus with a site in United States, this one is the 38th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2022, is one of 31 with no phase, and was the 56th registered.

Hydrocephalus

190 studies on the registry are indexed under Hydrocephalus; 52 are open to participants now.

Browse Hydrocephalus studies →

Open to participants now

22 of the 77 studies in Hydrocephalus with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Hydrocephalus studies recruiting now, 18 (58%) set no upper age limit and 6 (19%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Hydrocephalus with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study will be to evaluate a novel, minimally invasive method of treating hydrocephalus in adults. The eShunt® System includes a proprietary eShunt® Delivery System and the eShunt® Implant, a permanent implant that is deployed in a mildly invasive, neuro-interventional procedure. The eShunt® Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system.

Read the detailed description

This is a prospective, multi-center, open label, pilot study of the eShunt® System. The study population consists of patients with post-aneurysmal subarachnoid hemorrhage (SAH) treated for increased intracranial pressure (ICP) resulting in symptomatic hydrocephalus using an external ventricular drain (EVD) to facilitate CSF drainage and who cannot be "weaned" from the EVD after the hemorrhagic event.

After completion of the procedure to place the eShunt® device, the ICP will be monitored and recorded for up to 48 hours. Subjects will then return for follow-up visits that include standard neurological evaluations at 30, 60, 90, 180, and 365 days postimplantation; imaging will also be acquired at 30, 90 and 365 days after implant. Subjects will continue to attend follow-up visits every 180 days thereafter until the study is closed or up to 5 years post-implantation.

03

Conditions studied

  • Hydrocephalus
  • Hydrocephalus, Communicating

Browse trials for

Keywords

  • eShunt
  • Endovascular Shunt
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is ≥ 21 years old
  • Patient or legally authorized representative is able and willing to provide written
  • Post-aneurysmal SAH with Hunt and Hess Grades I-IV with EVD in place for at least 7 days with the need for a permanent CSF shunt determined through a failed EVD clamping trial defined as:

    1. Post-clamping ICP of > 20 cmH2O for 15 minutes, or
    2. Post-clamping ICP > 25 cmH2O for \< 15 minutes with patient intolerance to EVD clamping, or
    3. Significant radiographic signs of increasing ventriculomegaly, or
    4. Neurological decline attributable to ventriculomegaly and requiring CSF diversion
  • Clinical signs and symptoms of communicating hydrocephalus
  • Neurologically stable without evidence of severe vasospasm
  • Pre-procedure MRI confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by subject screening committee (SSC)
  • Pre-procedure CT confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by SSC

Exclusion criteria

Exclusion Criteria:

  • Presence of gross blood in CSF
  • Signs or symptoms of obstructive hydrocephalus
  • Active systemic infection or infection detected in CSF
  • Prior or existing shunts, endoscopic third ventriculostomy, or any previous surgical intervention for hydrocephalus
  • or to heparin or radiographic contrast agents which cannot be adequately pre-medicated, desensitized or where no alternative is available
  • Occlusion or stenosis of the internal jugular vein
  • Venous distension in the neck on physical exam
  • Medical conditions associated with prolonged elevation of jugular venous pressure, including jugular vein stenosis or stricture, right sided heart failure, cirrhosis of the liver, arterial venous fistulas in the arm for dialysis purposes, or an arterial venous fistula or malformation in the neck or brain
  • Atrial septal defect or patent foramen ovale identified on cardiac echocardiogram
  • History of bleeding diatheses, coagulopathy or will refuse blood transfusion in cases of emergency
  • Stroke or within 180 days of eShunt Procedure
  • Presence of a deep vein thrombosis superior to the popliteal vein
  • (INR) or Partial Thromboplastin Time (PTT) results outside of normal range (INR 0.8-1.4; PTT 25-35 seconds)
  • Presence of a posterior fossa tumor or mass
  • \< 1 year
  • Currently participating in another drug or device trial that could conflict with study data collection or follow-up
  • Pregnant
  • Unwilling or unable to comply with follow-up requirements
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Device Arm

    The Device Arm receives the eShunt® Implant

    Device: eShunt® Implant

Interventions

  • DeviceeShunt® Implant

    The eShunt® Implant is intended to drain excess cerebrospinal fluid from the intracranial subarachnoid space to the venous system as a less invasive therapy for treating hydrocephalus.

    Also known as: eShunt®, eShunt® system

06

What researchers measure

Primary outcomes

  1. Reduction in ICP

    At 24 to 48 hours after eShunt Implant deployment (with EVD remaining clamped) an ICP measurement that indicates: * ICP below 20 cmH2O with no periods longer than 15 minutes above 20 cmH2O * No episodes of ICP above 25 cmH2O with associated symptoms

    Time frame: 24-48 hours after eShunt Implant placement

Secondary outcomes

  1. Occurrence of Serious Adverse Events

    The number of device and/or procedure-related serious adverse events (SAEs) after the implant procedure will be calculated.

    Time frame: 90 days post procedure

  2. Incidence of clinically significant changes in Computed Tomography Imaging (CT/CTA) from baseline.

    Clinically significant changes from baseline CT images will be summarized

    Time frame: 1 year post procedure

  3. Number of participants with clinically significant changes in physical and neurologic examination assessments from baseline

    Clinically significant changes from baseline physical examination and neurologic examination assessments will be summarized

    Time frame: 1 year post procedure

  4. Summary of Adverse Events

    Tabulation of all Adverse Events collected in the study.

    Time frame: 90 days post procedure and at study completion

  5. Changes in Modified Rankin Scale Scores

    Changes in Modified Rankin Scale scores from baseline will be summarized.

    Time frame: 1 year post procedure

  6. Number of subjects requiring conversion to conventional CSF shunt

    Evaluate the need for CSF diversion by conventional CSF shunt insertion within 12 months after eShunt Implant deployment

    Time frame: 1 year post procedure

07

Study locations

2 sites
  • Yale University
    New Haven, Connecticut 06511, United States
  • Montefiore Medical Center Department of Neurosurgery
    New York, New York 10467, United States
08

References and documents

Publications

  • Lylyk P, Lylyk I, Bleise C, Scrivano E, Lylyk PN, Beneduce B, Heilman CB, Malek AM. First-in-human endovascular treatment of hydrocephalus with a miniature biomimetic transdural shunt. J Neurointerv Surg. 2022 May;14(5):495-9. doi: 10.1136/neurintsurg-2021-018136. Epub 2021 Dec 3. PubMed 34862267 ↗
  • Heilman CB, Basil GW, Beneduce BM, Malek AM. Anatomical characterization of the inferior petrosal sinus and adjacent cerebellopontine angle cistern for development of an endovascular transdural cerebrospinal fluid shunt. J Neurointerv Surg. 2019 Jun;11(6):598-602. doi: 10.1136/neurintsurg-2018-014445. Epub 2019 Jan 9. PubMed 30626626 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Sep 2023, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2022
First posted
Aug 15, 2022
StartActual
Sep 15, 2022
Primary completionActual
Sep 15, 2023
CompletionActual
Sep 15, 2023
Last update
Nov 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05501002
Lead sponsor
CereVasc Inc
Collaborators
AlvaMed, Inc., Simplified Clinical Data Systems, LLC
Responsible party
Sponsor
First posted
Aug 15, 2022
Start date
Sep 15, 2022
Primary completion
Sep 15, 2023
Completion
Sep 15, 2023
Last update
Nov 22, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion